Skip to main content
PRME
NASDAQ Life Sciences

Prime Medicine Posts $39M Q3 Operating Loss Days After $125M Raise

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$3.89
Mkt Cap
$705.556M
52W Low
$2.67
52W High
$5.91
52W Position info
46% above low
Off High info
34% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

PRME sits 46% above its 52-week low of $2.67.

Summary

Prime Medicine reported a Q3 loss from operations of $39.9 million and a net loss of $39.0 million, with operating expenses of $44.1 million. EPS came in at -$0.22. The burn lands just two days after the company priced a $125 million common stock offering at $3.50 a share for 35,714,286 shares, and follows an 8-K disclosing roughly $61.2 million of unrestricted cash at September 30. The offering has since closed, with the underwriters fully exercising their option to purchase additional shares, bringing the total raised to $143.7 million and extending the company's cash runway through 2027. The company entered the quarter with a going concern warning and has been funding a pipeline that includes PM647 (FDA IND clearance in September) and PM577a (first patient dosed in October). The loss itself is consistent with a clinical-stage biotech spending through its programs; the key question is how far the new capital extends operations.

At the time of this announcement, PRME was trading at $3.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $705.6M. The 52-week trading range was $2.67 to $5.91. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

PRME - Latest Insights

PRME
Nov 12, 2026, 4:11 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.89
Real-time Price: $3.74 info
Change: -$0.1461 (-4%) info
Market Cap: $678.476M info
PRME
Nov 12, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.90
Real-time Price: $3.74 info
Change: -$0.156 (-4%) info
Market Cap: $678.476M info
PRME
Nov 10, 2026, 9:41 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $3.76
Real-time Price: $3.74 info
Change: -$0.0155 (-0.41%) info
Market Cap: $678.476M info
PRME
Nov 10, 2026, 4:43 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $3.79
Real-time Price: $3.74 info
Change: -$0.046 (-1%) info
Market Cap: $678.476M info
PRME
Nov 10, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.80
Real-time Price: $3.74 info
Change: -$0.056 (-1%) info
Market Cap: $678.476M info